

BIOENVISION INC  
Form 8-K  
February 23, 2006

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

---

FORM 8-K

---

Current Report

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 23, 2006

---

BIOENVISION, INC.

(Exact name of registrant as specified in its charter)

---

Delaware

(State or other jurisdiction of incorporation)

000-24875  
(Commission File No.)

13-4025857  
(IRS Employer Identification No.)

Edgar Filing: BIOENVISION INC - Form 8-K

345 Park Avenue, 41st Floor

New York, New York 10154

(Address of principal executive offices and zip code)

---

Registrant's telephone number, including area code: (212) 750-6700

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
- 
- 
- 

**Item 8.01. Other Events.**

On February 23, 2006, the Company issued a press release reporting that the Company's clofarabine received a positive opinion from the European Medicines Agency. The press release is attached as Exhibit 99.1 to this report.

**Item 9.01 Financial Statements and Exhibits.**

**(c) Exhibits.**

99.1 Press Release dated February 23, 2006.

- 2 -

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOENVISION, INC.**

Dated: February 23, 2006

By: /s/ David P. Luci  
David P. Luci  
Chief Financial Officer, General Counsel and Corporate  
Secretary

- 3 -

---

**EXHIBIT INDEX**

99.1 Press Release dated February 23, 2006.

- 4 -

